Our study demonstrated that the tumor-suppressive effects of FXR could be partially attributed to FXR-mediated transcriptional activation of SHP, as ectopic expression of SHP impaired the proliferative and invasive potential of colon cancer cells. The gene discussed is NR1H4; the disease is malignant colon neoplasm.